# US 2019/0314445 A1 · Activation and expansion of nkg2c+ nk cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314445 A1
- Document ID: US20190314445A1
- Status: Published application
- Kind: A1
- Application number: 16/355,577
- Filed: 2019-03-15
- Published: 2019-10-17
- Earliest claimed: 2018-03-16
- Assignees: Deutsches Rheuma-Forschungszentrum Berlin
- Applicants: Deutsches Rheuma-Forschungszentrum Berlin
- Inventors: Chiara Romagnani; Timo Rückert; Quirin Hammer
- Web page: https://patentgrep.com/patent/US20190314445A1

## CPC

- A61K 38/03: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/20: Interleukins [IL]
- A61K 38/208: {IL-12}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to an isolated peptide for use as a medicament, wherein said peptide has 9 to 30 amino acids and comprises or consists of an amino acid sequence according to SEQ ID NO 1 (VMAPRTLXL), wherein X is an amino acid with a hydrophobic side chain (A, I, L, F, V, P, G), preferably V, L, I or F. The invention further relates to the peptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells. The invention further relates to the peptide of the invention for use in the treatment and/or prevention of a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2. Additionally, the invention relates to a genetically modified virus encoding a peptide comprising or consisting of a polypeptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells.

## Claims

### Claim 1

A method of treating a subject having or being at risk of developing a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2, the method comprising administering to said subject an effective amount of an isolated peptide of 9 to 30 amino acids comprising an amino acid sequence according to SEQ ID NO 1 (VMAPRTLXL), wherein X is an amino acid with a hydrophobic side chain (A, I, L, F, V, P, G), wherein the method expands and/or activates NKG2C+ natural killer (NK) cells.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said peptide comprises an amino acid sequence consisting of SEQ ID NO 2 (VMAPRTLFL).

### Claim 3 (depends on 1)

The method according to claim 1, wherein the medical condition is human cytomegalovirus (HCMV) infection.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the treatment inhibits reactivation of human HCMV.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the treatment reduces viral titers in an individual infected with HCMV.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the medical condition is cancer, wherein said cancer expresses HLA-G and HLA-E.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the expression of HLA-G and HLA-E is above levels in healthy control cells.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the cancer is selected from the group consisting of leukemia, Melanoma, choriocarcinoma, breast cancer, endometrial cancer, ovarian cancer, cervical cancer, esophageal squamous cell carcinoma, colorectal cancer, gastric cancer, hepatocellular carcinoma, glioblastoma, lung cancer, nasopharyngeal carcinoma, pancreatic adenocarcinoma, thyroid carcinoma and renal carcinoma.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the medical condition is a cancer associated with expression of HLA-G and HLA-E, wherein the cancer is identified by
a. providing a sample comprising cancer cells from the subject and
b. determining expression of HLA-G and HLA-E in said sample.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the medical condition is leukemia and the treatment inhibits reactivation of HCMV infections in subjects having received hematopoietic stem cell transplantation.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the peptide is administered in combination with an adjuvant that enhances production of, or comprises, IL-15, IL-12 and/or IL-18.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the peptide is administered in combination with a check point inhibitor.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the peptide is administered in combination with an inhibitor of a receptor selected from the group consisting of LILRB1, inhibitory KIRs, NKG2A, PD-1, CTLA-4, TIM-3, TIGIT and LAG-3.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the peptide is administered by a vector comprising or encoding the peptide according to claim 1, wherein the peptide is encoded by a nucleic acid molecule operably linked to a promoter for expression in mammalian subjects.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the vector is a genetically modified virus selected from the group consisting of attenuated HCMV, vaccinia virus, adenovirus, adeno-associated virus, retrovirus, and lentivirus.

### Claim 16 (depends on 1)

The method according to claim 1 for treating a subject having or being at risk of developing a medical condition associated with pathogenic cells expressing HLA-E and a peptide, the peptide comprising an amino acid sequence according to SEQ ID NO 1, the method comprising administering to said subject an effective amount of a genetically modified virus encoding a peptide comprising or consisting of a polypeptide according to claim 1.

### Claim 17 (depends on 1, 2)

An in vitro method for cultivating and/or expanding NKG2C+ natural killer (NK) cells, said method comprising:
providing leukocyte cells from a donor, wherein said leukocytes comprise NK cells;
contacting said NK cells with a peptide according to claim 1 or 2; and
optionally isolating or enriching for NKG2C+ NK cells.

### Claim 18 (depends on 17)

An isolated population of NKG2C+ natural killer (NK) cells produced by the method according to claim 17.

### Claim 19 (depends on 18)

A method of treating a subject having or being at risk of developing a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2, comprising administering to said subject an effective amount of an isolated population of NKG2C+ natural killer (NK) cells according to claim 18.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the medical condition is a cancer associated with expression of HLA-G and HLA-E.
